Press monitoring
Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine
2.2.2016 | Press monitoring
Lyon, France - February 2, 2016 - Sanofi Pasteur , the vaccines division of Sanofi , announced today that it has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
VALNEVA Evaluating Development of Zika Vaccine as Virus Spreads Through the Americas
2.2.2016 | Press monitoring
Lyon (France), February 2, 2016 - Valneva SE ("Valneva" or "the Company"), a leading pure play vaccine company, announces today that it is evaluating the development of a Zika vaccine as the virus is spreading rapidly through the Americas.
LivaNova PLC Announces FDA Approval of Stented Heart Valve CROWN PRT(TM) for Aortic Valve Disease
1.2.2016 | Press monitoring
LONDON, Feb. 01, 2016 (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) (the "Company"), a global medical technology company and a leader in the treatment of cardiovascular diseases, today announced it has been granted approval from the United States Food and Drug Administration (FDA) for its innovative stented aortic bioprosthesis...
Recombinant bacterium boosts production of compound that can relieve menopause symptoms
1.2.2016 | Press monitoring
A soy isoflavone derivative that goes by the scientific moniker, (S)-equol, has proven potent for mitigating menopausal symptoms. However, it has been impossible to produce in quantities sufficient for widespread commercial nutraceutical production. But now, a team of Korean researchers reports having constructed a recombinant bacterium which...
Novartis Foundation commemorates World Leprosy Day with its continued efforts to go the last mile toward elimination
31.1.2016 | Press monitoring
Basel, January 31, 2016 - On World Leprosy Day 2016, the Novartis Foundation calls for a greater global commitment to the fight against leprosy to support efforts towards zero transmission of the disease and to reduce stigma. The Novartis Foundation continues to work with partners around the world on early detection and treatment of leprosy,...
Actelion receives positive CHMP opinion for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension
29.1.2016 | Press monitoring
ALLSCHWIL, SWITZERLAND - 29 January 2016 - Actelion (SIX: ATLN) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), issued a positive opinion for the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), originally...
Seagrass genome sequence lends insights to salt tolerance
29.1.2016 | Press monitoring
International team sequenced a seagrass genome: that of the eelgrass Zostera marina, taken from the Archipelago Sea off Finland. Despite the name, eelgrasses aren't true grasses but rather completely submerged marine flowering plants, or angiosperms, and members of an ancient monocot family. To better understand the adaptations the plant made in...
LivaNova Receives Regulatory Approval in Japan for KORA 250
28.1.2016 | Press monitoring
LONDON, Jan. 28, 2016 (GLOBE NEWSWIRE) -- LivaNova, PLC (NASDAQ:LIVN) (LSE:LIVN) (the "Company"), a leading global medical technology company, announced today the approval of its new generation of full body MRI (Magnetic Resonance Imaging) conditional pacemakers by PMDA in Japan. KORA 250 SR and DR pacemakers allow patients to undergo MRI scans...
Hand sanitizer, antifreeze can preserve DNA
27.1.2016 | Press monitoring
A few simple products, such as hand sanitizer and antifreeze, can preserve DNA in samples collected by lay people for scientific research, a new University of Florida study shows. "This is great news because unlike high-concentration chemicals, such as 95 percent ethanol or pure propylene glycol -- which are expensive and hard to access -- these...
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma
25.1.2016 | Press monitoring
Heidelberg, Germany, January 25, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that it has entered into a clinical research collaboration in immuno-oncology with Merck (NYSE: MRK), known as MSD outside the United States...
